Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722271 | 0.90 | P2RX7 (0.51) | P2RX7MAPTCYP19A1HTR1DCDK4 | |
| SCHEMBL31362128 | 0.86 | P2RX7 (0.47) | P2RX7GRM2HTR1DCDK4CCND1 | |
| SCHEMBL26707490 | 0.86 | P2RX7 (0.47) | P2RX7GRM2HTR1DCDK4CCND1 | |
| SCHEMBL9911121 | 0.85 | CYP19A1 (0.45) | P2RX7MAPTCYP19A1CDC7CDK2 | |
| SCHEMBL31536146 | 0.82 | P2RX7 (0.47) | P2RX7MAPTCYP19A1HTR1DCDK4 | |
| SCHEMBL14723301 | 0.81 | NFATC1 (0.52) | P2RX7MAPTCYP19A1HTR1DCDK4 | |
| SCHEMBL18926929 | 0.77 | KCNH2 (0.50) | P2RX7MAPTCYP19A1CDC7CDK2 | |
| SCHEMBL28081827 | 0.77 | CYP19A1 (0.41) | P2RX7MAPTCYP19A1CDC7CDK2 | |
| SCHEMBL2127960 | 0.77 | KMO (0.56) | P2RX7MAPT | |
| SCHEMBL21245260 | 0.77 | P2RX7 (0.52) | P2RX7MAPTCYP19A1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | P2RX7 2180/4885MAPT 1161/4885GRM2 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.